Specifically, the serine-to-glycine substitution at residue 367 of AZIN1 was reported in a previous study; the editing may induce a conformational change and a cytoplasmic-to-nuclear translocation, which will result in tumor initiation and aggressive tumor progression (16). The gene discussed is AZIN1; the disease is neoplasm.